Atorvastatin (cancer chemoprevention context; statin class proxy)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-ATORVASTATIN-CHEMOPREVENTION |
|---|---|
| Type | Drug |
| Aliases | Atorvastatin (cancer chemoprevention)LipitorStatin (atorvastatin proxy)TorvacardАторвастатин (хіміопрофілактика раку; представник статинів) |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 SRC-WCRF-AICR-CUP-2018 |
Drug Facts
| Class | HMG-CoA reductase inhibitor (statin) |
|---|---|
| Mechanism | Competitively inhibits 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, blocking the rate-limiting step of mevalonate / cholesterol biosynthesis and upregulating hepatic LDL receptors. Cancer-prevention rationale: pleiotropic effects (decreased isoprenoid prenylation of Ras/Rho, anti-inflammatory, antiproliferative, pro-apoptotic) and downregulation of mevalonate-pathway tumor signaling. Observational meta-analyses suggest modest reductions in CRC, hepatocellular, esophageal, and prostate cancer incidence; RCT-level evidence remains absent. Primary regulatory indication is cardiovascular risk reduction. |
| Typical dosing | Cardiovascular-prevention dosing range used in any cancer-chemoprevention observational analyses: 10-80 mg PO once daily (with or without food). Typical starting dose 10-20 mg/day; titrate per LDL target. No specific oncology-prevention dose; observational signals span the entire dose range. Hepatic monitoring (baseline LFTs); CK only if symptomatic. Renal dose adjustment unnecessary. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-05-18 |
Notes
STUB — v0.2 chemoprevention-workstream authoring; pending two-Clinical- Co-Lead signoff per CHARTER §6.1 dev-mode. STATIN CLASS PROXY entity for cancer-chemoprevention discussions. Primary clinical use remains cardiovascular. Cancer-incidence signals from observational meta- analyses (Lancet 2012 Mayo collaborative pooled; multiple cohorts) are modest (~5-15% relative reductions in select sites) and have NOT translated to RCT-level cancer-prevention recommendations from USPSTF, NCCN, or ESMO. Engine should NOT recommend statin initiation for cancer prevention; appropriate when CV indications justify use. Class effect debated — atorvastatin used here as representative lipophilic statin (rosuvastatin / simvastatin similar mechanism).
Used By
No reverse references found in the YAML corpus.